GPCR/G protein
All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
- B6638 DH 97Summary: MT2 melatonin receptor antagonist
- B6641 SB 224289 hydrochlorideSummary: 5-HT1B receptor antagonist
- B6653 SB 216641 hydrochlorideSummary: h5-HT1B antagonist
- B6660 SDZ SER 082 fumarateSummary: 5-HT2B/2C receptor antagonist
- B6685 CP 94253 hydrochlorideSummary: 5-HT1B agonist
- B6688 GR 113808Summary: 5-HT4 receptor antagonist
- B6690 RX 821002 hydrochlorideSummary: α2-adrenoceptor antagonist
- B6699 ArvanilSummary: Cannabinoid CB1 and vanilloid TRPV1 (VR1) agonist
- B6703 VUF 5574Summary: human adenosine A3 receptor antagonist
- B6705 PD 81723Summary: Allosteric potentiator at the adenosine A1 receptor